Haselmeier gets pharmaceutical licence

Tuesday, February 12, 2019 by Haselmeier

Haselmeier is a leading solution provider for self-injection devices. As an innovative and strategic partner for pharmaceutical and biotechnology companies, Haselmeier develops and produces customised, unique self-injection systems that are used
worldwide. The quality, reliability and ease of use of these high-tech products play a key role in the therapeutic efficiency and quality of life of patients.

Haselmeier has been in possession of an allowance to manufacture pharmaceuticals since December 2018, which is done at the production site in Buchen, Odenwald, in accordance with §13 of the Medicines Act (Arzneimittelgesetz - AMG) or according to Art. 40 of Directive 2001/83/EC. Haselmeier can now offer pharmaceutical and biotechnological companies an
assembly, labelling and packaging service.

Konrad Betzler, chief quality officer of Haselmeier: "I am pleased that, after extensive preparatory work and in close coordination with the responsible GMP supervisory authority, we have now received the manufacturing permit."

Haselmeier will in future assemble the cartridges supplied by customers for the respective therapies with the injection pens as well as label and package the combination products. This service also includes the manufacture of batches for stability testing. Haselmeier thus offers important complete solutions, for example for pharmaceutical companies in the production of
small and medium-sized series for clinical studies as well as for biotech start-ups.


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.